US approves new oral weight-loss pill developed by Eli Lilly
📖 Full Retelling
<p>Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy</p><p>The US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly.</p><p>Known as orforglipron or brand name Foundayo, the once-daily tablet becomes the second GLP-1 drug in pill form to hit the market in a short span of time, arriving a
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
US approves new oral weight-loss pill developed by Eli Lilly Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy The US Food and Drug Administration gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly. Known as orforglipron or brand name Foundayo, the once-daily tablet becomes the second GLP-1 drug in pill form to hit the market in a short span of time, arriving after Novo Nordisk’s Wegovy pill received approval in December. The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works similarly to widely used injectable treatments by mimicking a natural hormone that helps regulate appetite and feelings of fullness. “Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment,” said David A Ricks, chair and CEO of Eli Lilly, in a statement . “We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications.” Patients taking Foundayo are generally expected to begin with the smallest dose and gradually increase it to help limit side effects. Unlike the Wegovy pill, which must be taken first thing in the morning on an empty stomach, this medication can be taken at any point during the day without regard to meals. The starting dose is projected to cost around $149 per month for those paying without insurance, similar to the Wegovy pill. Higher strengths may reach prices of up to $349 monthly. It remains uncertain how widely private insurance plans will cover it. However, under a proposal from the Trump administration, Medicare coverage could begin for certain patients as early as this summer, with copayments potentially as low as $50 per month. This decision comes as th...
Read full article at source